SCHEMBL4873314

SCHEMBL4873314

Cc1cccc2cccc(CN3CCC(c4cn(CC5CO5)c5ccc(F)cc45)CC3)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.45
OPRL1 P41146 4/20 0.45
OPRK1 P41145 2/20 0.45
DRD2 P14416 2/20 0.45
SLC6A4 P31645 2/20 0.45
HRH2 P25021 7/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CHRM1 P11229 2/20 0.37
KCNH2 Q12809 1/20 0.36
CACNB4 O00305 1/20 0.34
CACNA1A O00555 1/20 0.34
CACNA1G O43497 1/20 0.34
CACNG3 O60359 1/20 0.34
CACNA1F O60840 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNB3 P54284 1/20 0.34
CACNA2D1 P54289 1/20 0.34
CACNG7 P62955 1/20 0.34
CACNA1B Q00975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14280689 0.82 OPRM1 (0.64) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL4880602 0.77 OPRM1 (0.75) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL14280688 0.76 OPRL1 (0.65) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL14529394 0.74 DRD2 (0.50) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL14280678 0.72 OPRM1 (0.44) OPRM1OPRL1OPRK1DRD2HRH2
SCHEMBL4881230 0.70 OPRL1 (0.67) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL4881232 0.70 OPRL1 (0.67) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL4062260 0.70 HRH2 (0.57) OPRM1OPRL1OPRK1HRH2
SCHEMBL4873307 0.69 OPRM1 (0.51) OPRM1OPRL1OPRK1DRD2SLC6A4
SCHEMBL4873298 0.66 OPRM1 (0.49) OPRM1OPRL1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-01-17 US disclosed
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-01-17 US disclosed
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-01-17 US disclosed
WO-2007050381-A2 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015214-A1 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS OGFRL1, OPRL1, ORMDL3 OPRM1 11/4885OPRL1 2/4885OPRK1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.